NO136843C - Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin - Google Patents

Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin

Info

Publication number
NO136843C
NO136843C NO62/73A NO6273A NO136843C NO 136843 C NO136843 C NO 136843C NO 62/73 A NO62/73 A NO 62/73A NO 6273 A NO6273 A NO 6273A NO 136843 C NO136843 C NO 136843C
Authority
NO
Norway
Prior art keywords
pyrrolo
pyrazine
dihydro
preparation
therapeutically active
Prior art date
Application number
NO62/73A
Other languages
English (en)
Norwegian (no)
Other versions
NO136843B (no
Inventor
Claude Cotrel
Claude Jeanmart
Mayer Naous Messer
Original Assignee
Rhone Poulenc Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7200505A external-priority patent/FR2166314A1/fr
Priority claimed from FR7239731A external-priority patent/FR2205318A2/fr
Application filed by Rhone Poulenc Sa filed Critical Rhone Poulenc Sa
Publication of NO136843B publication Critical patent/NO136843B/no
Publication of NO136843C publication Critical patent/NO136843C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO62/73A 1972-01-07 1973-01-05 Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin NO136843C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7200505A FR2166314A1 (en) 1972-01-07 1972-01-07 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls
FR7239731A FR2205318A2 (en) 1972-11-09 1972-11-09 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls

Publications (2)

Publication Number Publication Date
NO136843B NO136843B (no) 1977-08-08
NO136843C true NO136843C (no) 1977-11-16

Family

ID=26216824

Family Applications (1)

Application Number Title Priority Date Filing Date
NO62/73A NO136843C (no) 1972-01-07 1973-01-05 Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin

Country Status (22)

Country Link
US (1) US3862149A (fr)
JP (3) JPS523952B2 (fr)
AR (1) AR195097A1 (fr)
AT (1) AT323181B (fr)
AU (1) AU466586B2 (fr)
BE (1) BE793730A (fr)
CA (1) CA991183A (fr)
CY (1) CY915A (fr)
DD (1) DD102698A5 (fr)
DE (1) DE2300491C3 (fr)
DK (1) DK139359B (fr)
FI (1) FI54124C (fr)
GB (1) GB1358680A (fr)
HK (1) HK60077A (fr)
HU (1) HU164821B (fr)
IE (1) IE37056B1 (fr)
IL (1) IL41232A (fr)
LU (1) LU66800A1 (fr)
NL (1) NL7217852A (fr)
NO (1) NO136843C (fr)
OA (1) OA04285A (fr)
SE (1) SE398503B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2322601A1 (fr) * 1975-09-04 1977-04-01 Rhone Poulenc Ind Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
JPS5680585A (en) * 1979-11-30 1981-07-01 Toyoda Gosei Kk High pressure hose
JPS57144860A (en) * 1981-03-04 1982-09-07 Matsushita Electric Ind Co Ltd Secondary side water pressure controller for water cooler
US4590189A (en) * 1982-04-02 1986-05-20 Takeda Chemical Industries, Ltd. Condensed pyrrolinone derivatives, their production and use
JPS6169773A (ja) * 1984-09-14 1986-04-10 Takeda Chem Ind Ltd イソインドリノン誘導体
JPS6297400U (fr) * 1985-12-09 1987-06-20
FR2607504B1 (fr) * 1986-12-02 1989-01-27 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
WO1993010787A1 (fr) * 1991-12-02 1993-06-10 Sepracor, Inc. Procedes et compositions therapeutiques de troubles du sommeil, d'attaques epileptiques et d'autres troubles au moyen de zopiclone (+) optiquement pure
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
AU3275993A (en) * 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
AU4060599A (en) 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
US6339086B1 (en) * 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
ES2203319B1 (es) * 2002-04-03 2005-03-01 Universidad De Oviedo Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
CA2548917C (fr) 2003-12-11 2014-09-23 Sepracor Inc. Combinaison d'un sedatif et d'un modulateur des neurotransmetteurs, et methodes permettant d'ameliorer la qualite du sommeil et de traiter la depression
CA2614209A1 (fr) * 2005-07-06 2007-01-11 Sepracor Inc. Combinaisons d'un eszopiclone et d'un o-desmethylvenlafaxine, et methodes de traitement de la menopause et de l'humeur, de l'anxiete et des troubles cognitifs
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007088073A1 (fr) * 2006-02-03 2007-08-09 Synthon B.V. Resolution de la zopiclone en utilisant de l'acide l-tartrique
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (fr) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation de neurogenèse par des agents nootropes
US20080027223A1 (en) * 2006-03-23 2008-01-31 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
EP2007768A2 (fr) * 2006-04-20 2008-12-31 Teva Pharmaceutical Industries Ltd Procédés de préparation d'une forme cristalline a d'eszopiclone, d'une eszopiclone sensiblement pure et d'une eszopiclone optiquement enrichie
CN101058581B (zh) * 2006-04-21 2011-06-08 天津天士力集团有限公司 右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008002629A1 (fr) * 2006-06-26 2008-01-03 Teva Pharmaceutical Industries Ltd. Procédé de préparation de zopiclone
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US7786304B2 (en) * 2006-11-06 2010-08-31 Centaur Pharmaceutical Pvt. Ltd. Process for the preparation of eszopiclone
US20080287447A1 (en) * 2007-01-31 2008-11-20 Nina Finkelstein Methods for preparing eszopiclone
US20080305171A1 (en) * 2007-06-07 2008-12-11 Kristin Anne Arnold Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
US20090018336A1 (en) * 2007-06-25 2009-01-15 Nina Finkelstein Racemization process of R-zopiclone
EP2020403A1 (fr) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Procédé pour la résolution de zopiclone et de composés intermédiaires
WO2009063486A2 (fr) * 2007-08-06 2009-05-22 Usv Limited Processus de préparation d'isomère dextrogyre de 6-(5-chloro-pyrid-2-yi)-5-[(4-méthyl -1-piperazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo [3,4-b] pyrazine (eszopiclone)
AU2008346110A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2747000C (fr) * 2007-12-19 2013-09-03 Sunovion Pharmaceuticals Inc. Sels de maleate, de besylate et de l-malate de 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]-pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CN100467471C (zh) * 2007-12-19 2009-03-11 齐鲁天和惠世制药有限公司 佐匹克隆的制备方法
WO2009085988A1 (fr) * 2007-12-19 2009-07-09 Sepracor Inc. Sels de 6-(5-chloro-2-pyridyl)-5-[(4-méthyl-1-pipérazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b] pyrazine
US8212036B2 (en) * 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
WO2010088385A1 (fr) 2009-01-30 2010-08-05 Sepracor Inc. Comprimés de 6-(5-chloro-2-pyridyl)-5-[(4-méthyl-1-pipérazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine enrobés, et procédé pour mesurer l'efficacité de l'enrobage
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
CN105399745A (zh) * 2015-12-17 2016-03-16 天津华津制药有限公司 一种吡嗪并羟基吡咯烷酮类化合物的制备方法
EP3468545A4 (fr) 2016-06-08 2020-07-22 President and Fellows of Harvard College Procédés et compositions pour réduire le dysfonctionnement tactile et l'anxiété associés au trouble du spectre de l'autisme, au syndrome de rett et au syndrome de l'x fragile
CN106220630B (zh) * 2016-07-23 2019-12-10 迪嘉药业集团有限公司 一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
US11434244B2 (en) 2018-05-29 2022-09-06 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment

Also Published As

Publication number Publication date
JPS5248687A (en) 1977-04-18
SE398503B (sv) 1977-12-27
BE793730A (fr) 1973-07-05
DK139359B (da) 1979-02-05
CY915A (en) 1977-12-23
DE2300491B2 (de) 1977-09-08
AR195097A1 (es) 1973-09-10
LU66800A1 (fr) 1973-07-18
NL7217852A (fr) 1973-07-10
US3862149A (en) 1975-01-21
AU466586B2 (en) 1975-10-30
HU164821B (fr) 1974-04-11
JPS523952B2 (fr) 1977-01-31
OA04285A (fr) 1979-12-31
JPS5231358B2 (fr) 1977-08-13
AU5075473A (en) 1974-07-04
JPS4876892A (fr) 1973-10-16
HK60077A (en) 1977-12-09
DD102698A5 (fr) 1973-12-20
IL41232A (en) 1975-12-31
DE2300491A1 (de) 1973-07-19
FI54124B (fi) 1978-06-30
FI54124C (fi) 1978-10-10
AT323181B (de) 1975-06-25
IE37056L (en) 1973-07-07
DK139359C (fr) 1979-07-09
IL41232A0 (en) 1973-03-30
NO136843B (no) 1977-08-08
JPS535315B2 (fr) 1978-02-25
DE2300491C3 (de) 1978-05-18
GB1358680A (en) 1974-07-03
JPS5248688A (en) 1977-04-18
IE37056B1 (en) 1977-04-27
CA991183A (fr) 1976-06-15

Similar Documents

Publication Publication Date Title
NO136843C (no) Analogifremgangsm}te til fremstilling av terapeutisk aktive derivater av 5,6-dihydro-pyrrolo (3,4-b) pyrazin
NO140301C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazo(5,1-f)-as-triaziner
SE402592B (sv) Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner
NO137012C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive pyrazolo (1,5-a)-pyrimidiner
NO136094C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive d-1-(4-amino-fenyl)-2-alkylamino-etanol-derivater.
NO138565C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperazinyl-propyl-1,2,4-triazolinonderivater
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
NO137966C (no) Analogifremgangsmaate til fremstilling av antibakterielt virksomme 5-oksopyrido-(2,3-d)-pyrimidinderivater
SE389499B (sv) Analogiforfarande for framstellning av triazolo(4,3-a)(1,4)bensodiazepin-derivat
NO136251C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive pyridazin-derivater.
SE402012B (sv) Analogiforfarande for framstellning av s-triazolo(1,5-a)(1,4)diazepinderivat
SE410604B (sv) Analogiforfarande for framstellning av pyrazolo(3,4-e)(1,4)diazepinforeningar
SE411451B (sv) Analogiforfarande for framstellning av derivat av imidazo(4,5-b)pyridiner
NO136574C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive pyrimidinderivater.
NO139735C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimido(4,5-b)kinolin-4(3h)-on-derivater
NO137728C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrasi-4-oksyd-derivater
NO741752L (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminoderivater av pyrazolopyridin-ketoner.
SE397093B (sv) Forfarande for framstellning av oktahydro-oxazolo(3,2-a)pyrrolo(2,1-c)pyrazinderivat
NO140860C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive triazolo-1,5-benzodiazepiner
SE380804B (sv) Anologiforfarande for framstellning av s-triazolo (1,5-a) (1,4)
SE398122B (sv) Analogiforfarande for framstellning av pyrazino/1,2-a/indol-2-karboxamidiner
SE407685B (sv) Analogiflrfarande for framstellning av s-triazolo(4,3-a)(1,4)bensodiazepinderivat
NO137696C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzodiazepin-derivater
NO137900C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, basisk substituerte teofyllin-derivater
NO138656C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 2-amino-4h -pyraner